Clincosm LogoSign in Get a demo

esophageal squamous cell carcinoma

Showing 51 - 75 of 216
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Moderately hypofractionated conformal radiation combined With S-1)

Completed
  • Esophageal Squamous Cell Carcinoma
  • Moderately hypofractionated conformal radiation combined With S-1
  • Guangzhou, Guangdong, China
    Hui Liu
Oct 25, 2022

Esophageal Squamous Cell Carcinoma Trial (AK104)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Oct 25, 2022

Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal

Recruiting
  • Breast Cancer
  • +15 more
  • ATRC-101
  • +2 more
  • Phoenix, Arizona
  • +10 more
Sep 28, 2022

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Penpulimab Combined With CRT)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Penpulimab Combined With CRT
  • Shanghai, Shanghai, China
    Zhongshan Hospital
Sep 28, 2022

Esophageal Squamous Cell Carcinoma Trial (Envafolimab, Albumin-Bound Paclitaxel, Carboplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Sep 21, 2022

Esophageal cAncer Screening Trial

Completed
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Sponge cytological test
  • Shanghai, Shanghai, China
    Changhai Hospital
Sep 17, 2022

Esophageal Squamous Cell Carcinoma Trial in Beijing (Pembrolizumab)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 13, 2022

Solid Tumors, Metastatic Melanoma, NSCLC Trial in Worldwide (RO7247669)

Recruiting
  • Solid Tumors
  • +3 more
  • San Diego, California
  • +20 more
Aug 19, 2022

Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tislelizumab, Ociperlimab, Placebo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Hefei, Anhui, China
  • +85 more
Aug 19, 2022

Esophageal Squamous Cell Carcinoma Trial in Hanzhou, Ningbo (Neoadjuvant Radiotherapy, Neoadjuvant Chemotherapy, Immunotherapy)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Neoadjuvant Radiotherapy
  • +2 more
  • Hanzhou, Zhejiang, China
  • +2 more
Aug 16, 2022

Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma Trial in United Kingdom, United States

Terminated
  • Pancreatic Adenocarcinoma
  • +13 more
  • San Francisco, California
  • +7 more
Aug 17, 2022

NSCLC, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma Trial in San Antonio, West Valley City,

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +4 more
  • San Antonio, Texas
  • +2 more
Aug 15, 2022

Esophageal Squamous Cell Carcinoma Trial in Tokyo (FLOT therapy)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • FLOT therapy
  • Tokyo, Japan
    Keio University Hospital
Aug 15, 2022

Esophageal Squamous Cell Carcinoma, HER-2 Protein Overexpression, HER-2 Gene Amplification Trial in Copenhagen, Odense

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • +2 more
  • Copenhagen, Region H, Denmark
  • +1 more
Aug 10, 2022

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Sintilimab)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Aug 8, 2022

Esophageal Squamous Cell Carcinoma Trial (QL1706)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • (no location specified)
Aug 4, 2022

Esophageal Squamous Cell Carcinoma Trial in China (Sitravatinib, Tislelizumab, Docetaxel)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Hefei, Anhui, China
  • +29 more
Jul 28, 2022

Esophageal Squamous Cell Carcinoma, Locally Advanced Carcinoma Trial in Nanjing (Tislelizumab, 5-FU, cis Platinum)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Locally Advanced Carcinoma
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Jul 19, 2022

Esophageal Squamous Cell Carcinoma Trial in Nanjing (Sintilimab, Liposomal Paclitaxel + Cisplatin + S-1)

Active, not recruiting
  • Esophageal Squamous Cell Carcinoma
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Jul 16, 2022

NSCLC, Carcinoma, Renal Cell, Esophageal Squamous Cell Carcinoma Trial (QEQ278)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +3 more
  • QEQ278
  • (no location specified)
Jul 14, 2022

Esophageal Squamous Cell Carcinoma Trial in Nanjing, Shanghai (Radiotherapy)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Radiotherapy
  • Nanjing, Jiangsu, China
  • +2 more
Jul 14, 2022

Efficacy of PD-1 Monoclonal Antibody

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • PD-1 Inhibitor
    • Guangzhou, China
      Nanfang Hospital
    Jul 5, 2022

    Local Advanced Esophageal Carcinoma

    Recruiting
    • Esophageal Squamous Cell Carcinoma
      • Shanghai, Shanghai, China
        Fudan University Shanghai cancer center
      Jun 16, 2022

      Esophageal Squamous Cell Carcinoma Trial in Shanghai (Two-Field lymph node dissection, Three-Field lymph node dissection)

      Not yet recruiting
      • Esophageal Squamous Cell Carcinoma
      • Two-Field lymph node dissection
      • Three-Field lymph node dissection
      • Shanghai, Shanghai, China
        Shanghai Zhongshan Hospital
      Jun 15, 2022

      Esophageal Squamous Cell Carcinoma Trial in Shanghai (Nivolumab, Cisplatin, Paclitaxel)

      Recruiting
      • Esophageal Squamous Cell Carcinoma
      • Shanghai, China
        180 Fenglin Road
      Jun 12, 2022